Enanta Pharmaceuticals (ENTA) Non Operating Income (2012 - 2026)
Enanta Pharmaceuticals (ENTA) posted Non Operating Income of -$1.2 million for Q1 2026, down 86.38% on a QoQ basis from -$661000.0 in Q4 2025, and down 313.15% year-over-year from $578000.0 in Q1 2025.
Enanta Pharmaceuticals (ENTA) Non Operating Income (2012 - 2026) Analysis & Trends
Enanta Pharmaceuticals' Non Operating Income history runs 15 years deep, the most recent figure standing at -$1.2 million for Q1 2026.
- Quarterly Non Operating Income fell 313.15% year-over-year to -$1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.5 million (down 146.91% YoY) and the FY2025 annual result came in at $1.8 million, down 53.88% from the prior year.
- Non Operating Income was -$1.2 million for Q1 2026 at Enanta Pharmaceuticals, down from -$661000.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $3.9 million in Q2 2023 and bottomed at -$1.2 million in Q1 2026.
- A 5-year average of $787117.6 and a median of $714000.0 in 2022 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2023 — Non Operating Income jumped 883.72% — and 2026, when it sank 313.15%.
- Enanta Pharmaceuticals' Non Operating Income stood at $993000.0 in 2022, then dropped by 13.7% to $857000.0 in 2023, then retreated by 2.33% to $837000.0 in 2024, then slumped by 178.97% to -$661000.0 in 2025, then plunged by 86.38% to -$1.2 million in 2026.
- Business Quant data shows ENTA's Non Operating Income at -$1.2 million in Q1 2026, -$661000.0 in Q4 2025, and -$282000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -9.22 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 188.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 5.75 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -8.59 Mn |
| 10 | Enanta Pharmaceuticals | 376.07 Mn | 212.29 Mn | - | -1.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.23 Mn |
| Dec 31, 2025 | -661,000.00 |
| Sep 30, 2025 | -282,000.00 |
| Jun 30, 2025 | 667,000.00 |
| Mar 31, 2025 | 578,000.00 |
| Dec 31, 2024 | 837,000.00 |
| Sep 30, 2024 | 668,000.00 |
| Jun 30, 2024 | 1.13 Mn |
| Mar 31, 2024 | 1.25 Mn |
| Dec 31, 2023 | 857,000.00 |
| Sep 30, 2023 | 1.51 Mn |
| Jun 30, 2023 | 3.87 Mn |
| Mar 31, 2023 | 1.84 Mn |
| Dec 31, 2022 | 993,000.00 |
| Sep 30, 2022 | 714,000.00 |
| Jun 30, 2022 | 393,000.00 |
| Mar 31, 2022 | 255,000.00 |
| Dec 31, 2021 | 258,000.00 |
| Sep 30, 2021 | 333,000.00 |
| Jun 30, 2021 | 439,000.00 |